Please ensure Javascript is enabled for purposes of website accessibility

Is AstraZeneca a Bargain Buy?

By David Jagielski – Aug 14, 2021 at 6:37AM

Key Points

  • AstraZeneca has been delivering strong growth numbers of late, and it's not running out of opportunities anytime soon.
  • The recent acquisition of Alexion will expand its portfolio and give it a high-growth drug in Ultomiris.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even if you aren't crazy about the company's COVID-19 vaccine, this is still a growth investment worth considering for your portfolio.

AstraZeneca (AZN 0.45%) has been an underwhelming stock to own over the past year. Its shares are up less than 2% while the S&P 500 has soared more than 32%.

Part of the lackluster showing is likely due to its COVID-19 vaccine, which has faced some bad press this year, based both on questions about its overall effectiveness and on its potentially causing blood clots. While it's not currently being sold in the U.S., AstraZeneca's vaccine is approved for use in other parts of the world, including the European Union, the U.K., and Canada, and it is possible that the U.S. Food and Drug Administration could approve it later this year.

But AstraZeneca is more than just a COVID stock, and it has plenty of growth opportunities ahead. Could this overlooked stock even be a bargain buy, given how ridiculously overpriced some companies are right now?

A couple smiling and talking with an advisor.

Image source: Getty Images.

The business is coming off a strong earnings report

On July 29, AstraZeneca released its earnings for the first half of 2021. There were many positives in the report, including 23% revenue growth and sales of $15.5 billion; the latter included a $1.2 billion boost from its COVID-19 vaccine. AstraZeneca also generated 15% revenue growth in its biopharmaceuticals division and 19% growth from oncology-related revenue (its largest segment). Excluding revenue from the vaccine, the company's overall sales growth was still positive, at 14% year over year. AstraZeneca's earnings per share of $1.61 were also a 37% improvement from the prior-year period, which includes a negative $0.04 impact this past quarter due to the vaccine (the company previously pledged to make the vaccine without seeking a profit on it during the pandemic).

As well as the company did this past period, it could do even better in future quarters and years.

More growth opportunities lie ahead

AstraZeneca still plans to apply for authorization of its vaccine in the U.S. before the end of this year. However, since the FDA has already given an Emergency Use Authorization to multiple COVID vaccines and more than 50% of the U.S. population has been vaccinated so far, even that potential green light might not bring in too much revenue.

Another growth opportunity will come from its $39 billion acquisition of Alexion Pharmaceuticals, a biopharmaceutical company, which it completed on July 21. Alexion has many orphan drugs in its portfolio that treat rare conditions. One of the most attractive is Ultomiris, which generated $1.1 billion in revenue last year -- more than tripling the $339 million it brought in a year earlier. Ultomiris treats patients with paroxysmal nocturnal hemoglobinuria, a rare blood disease that can be life-threatening. AstraZeneca's management projects that the Alexion acquisition will help to boost this fiscal year's revenue by at least 20%.

Over the long term, there's even more potential for AstraZeneca, which had a total of 160 projects in its pipeline -- including 13 that are in late stages -- even before the acquisition. Alexion's pipeline has contributed another 30 therapies.

How AstraZeneca's stock compares with other vaccine makers

Compared to Johnson & Johnson and Pfizer, AstraZeneca's stock looks fairly valued today, trading at a forward price-to-earnings multiple of about 13:

AZN PE Ratio (Forward) Chart

AZN PE Ratio (Forward) data by YCharts.

While it may not be a dirt cheap buy, AstraZeneca doesn't look expensive, either. And it has the potential to be a bargain, depending on how well its pipeline pans out. Its sales and profits could grow significantly over the years, especially now that it's expanded its portfolio with the acquisition of Alexion.

Is AstraZeneca stock a buy?

In August, investment bank SVB Leerink upgraded its price target for AstraZeneca's stock from $63 to $69. That price represents an upside of more than 23% from where it trades today.

I wouldn't suggest this as a healthcare stock to buy if you're simply looking for a company that will do well due to its COVID-19 vaccine. But if you're willing to hang on for the long haul, AstraZeneca could be a great buy -- one that delivers returns far higher than 23%. With so many projects in its pipeline, there's likely to be some strong growth in its future. Another reason to consider the stock for the long haul would be for its dividend yield, currently 2.5% -- well above the S&P 500 average of 1.3%.

Although AstraZeneca hasn't been a great investment over the past 12 months, there are plenty of reasons to remain bullish on the stock in the years ahead.

SVB Financial provides credit and banking services to The Motley Fool. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends SVB Financial Group. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.47 (0.45%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.